BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36594099)

  • 1. Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition.
    Monteiro-Reis S; Miranda-Gonçalves V; Guimarães-Teixeira C; Martins-Lima C; Lobo J; Montezuma D; Dias PC; Neyret-Kahn H; Bernard-Pierrot I; Henrique R; Jerónimo C
    Int J Biol Sci; 2023; 19(1):1-12. PubMed ID: 36594099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression.
    Martins-Lima C; Miranda-Gonçalves V; Lobo J; Constâncio V; Leite-Silva P; Guimarães-Teixeira C; Monteiro-Reis S; Sequeira JP; Cantante M; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
    Cell Oncol (Dordr); 2022 Feb; 45(1):135-149. PubMed ID: 35064910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression.
    Lobo J; Monteiro-Reis S; Guimarães-Teixeira C; Lopes P; Carneiro I; Jerónimo C; Henrique R
    J Transl Med; 2020 Aug; 18(1):303. PubMed ID: 32758253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-β-induced transgelin promotes bladder cancer metastasis by regulating epithelial-mesenchymal transition and invadopodia formation.
    Chen Z; He S; Zhan Y; He A; Fang D; Gong Y; Li X; Zhou L
    EBioMedicine; 2019 Sep; 47():208-220. PubMed ID: 31420300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressive microRNA‑138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.
    Yamasaki T; Seki N; Yamada Y; Yoshino H; Hidaka H; Chiyomaru T; Nohata N; Kinoshita T; Nakagawa M; Enokida H
    Int J Oncol; 2012 Sep; 41(3):805-17. PubMed ID: 22766839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
    Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
    Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non-coding RNA VIM-AS1 promotes prostate cancer growth and invasion by regulating epithelial-mesenchymal transition.
    Zhang Y; Zhang J; Liang S; Lang G; Liu G; Liu P; Deng X
    J BUON; 2019; 24(5):2090-2098. PubMed ID: 31786880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial-to-mesenchymal transition based diagnostic and prognostic signature markers in non-muscle invasive and muscle invasive bladder cancer patients.
    Singh R; Singh UP; Agrawal V; Garg M
    Mol Biol Rep; 2022 Aug; 49(8):7541-7556. PubMed ID: 35593896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
    Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
    Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition.
    Liang W; Hao Z; Han JL; Zhu DJ; Jin ZF; Xie WL
    Urol Oncol; 2014 Aug; 32(6):855-63. PubMed ID: 24968949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of Vimentin Antisense RNA 1 and its correlation with other epithelial to mesenchymal transition markers in oral cancers.
    Bozgeyik E; Ege B; Koparal M; Ceylan O
    Pathol Res Pract; 2022 Apr; 232():153807. PubMed ID: 35202907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulated vimentin and upregulated E-cadherin in T1 stage non-small-cell lung cancer: does it suggest a mesenchymal-epithelial transition?
    Luo T; Wang L; Wu P; Gong W; Chen W; Zhao H; Zheng Z
    Neoplasma; 2017; 64(5):693-699. PubMed ID: 28592120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirtuins' Deregulation in Bladder Cancer: SIRT7 Is Implicated in Tumor Progression through Epithelial to Mesenchymal Transition Promotion.
    Monteiro-Reis S; Lameirinhas A; Miranda-Gonçalves V; Felizardo D; Dias PC; Oliveira J; Graça I; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32344886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PODNL1 promotes cell migration and regulates the epithelial/mesenchymal transition process in bladder cancer.
    Liu X; He Y; Tong Y; Huang Q; Shang H; Chen Z; Tang K
    Biochem Biophys Res Commun; 2022 Sep; 620():165-172. PubMed ID: 35797736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZEB1 promotes tumorigenesis and metastasis in hepatocellular carcinoma by regulating the expression of vimentin.
    Qin Y; Yu J; Zhang M; Qin F; Lan X
    Mol Med Rep; 2019 Mar; 19(3):2297-2306. PubMed ID: 30664206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Noncoding RNA VIM Antisense RNA 1 (VIM-AS1) Plays an Important Role in Development of Preeclampsia by Regulation of Epithelial Mesenchymal Transition.
    Zhao X; Jiang X; Liu Z; Zhou M; Zhang J; Wang X; Li X
    Med Sci Monit; 2019 Nov; 25():8306-8314. PubMed ID: 31685789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expressions of EMT markers in pan-RAS-pERK1/2-positive tumors improve diagnosis and prognosis assessment of non-muscle invasive bladder cancer and muscle invasive bladder cancer patients.
    Tripathi K; Maurya N; Goel A; Singhai A; Garg M
    Mol Cell Biochem; 2023 Jun; 478(6):1169-1190. PubMed ID: 36239855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.
    Chakravarthi BVSK; Rodriguez Pena MDC; Agarwal S; Chandrashekar DS; Hodigere Balasubramanya SA; Jabboure FJ; Matoso A; Bivalacqua TJ; Rezaei K; Chaux A; Grizzle WE; Sonpavde G; Gordetsky J; Netto GJ; Varambally S
    Neoplasia; 2018 Sep; 20(9):894-904. PubMed ID: 30121007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
    Singh R; Ansari JA; Maurya N; Mandhani A; Agrawal V; Garg M
    Clin Genitourin Cancer; 2017 Apr; 15(2):e187-e197. PubMed ID: 27601277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.